Myrexis IncOver The Counter Market:MYRX
- LAST PRICE0.0105
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0105
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Myrexis Inc | 362.0K | 0.0x | --- |
RespireRx Pharmaceuticals Inc | 292.3K | -0.1x | --- |
Life Stem Genetics Inc | 393.3K | -0.1x | --- |
Better Therapeutics Inc | 398.9K | 0.0x | --- |
Allarity Therapeutics Inc | 475.8K | 0.0x | --- |
ContraFect Corp | 224.8K | 0.0x | --- |
Company Information
Myrexi, Inc. is a development-stage company. The Company was a biopharmaceutical company that generated a pipeline of differentiated drug candidates in oncology and autoimmune diseases. In February 2012, it announced that the Company has suspended development activity on all of its preclinical and clinical programs and retained Stifel Nicolaus Weisel, an investment banking firm, to assist in reviewing and evaluating a full range of strategic alternatives to enhance shareholder value. The Company determines to pursue the acquisition of one or more commercial-stage biopharmaceutical assets, with the goal of building a commercial-stage biopharmaceutical company. The Company operates in pharmaceutical development and related research activities. The Company’s revenues were derived from research performed in the United States and, all of the Company’s long-lived assets are located in the United States.
Contact Information
- Headquarters
- 600 Fifth Avenue, 2nd FloorNEW YORK, NY, United States 10020
- Phone
- 801-214-7800
- Fax
- 302-645-1280
Executives
- President, Chief Executive Officer, Director
- Jonathan Couchman
- Treasurer, Secretary
- Andrea Kendell
- Independent Director
- Michael Pearce
- Independent Director
- Steven Scheiwe
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $362.0K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 34.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.37 |
EPS | $-0.42 |
Book Value | $0.03 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
